Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a rheumatic disease.~* Starting treatment with glucocorticoids in a dosage of 7.5 mg prednisone equivalent daily or higher.~* All ethnic groups and races.~Exclusion Criteria:~* Glucocorticoid treatment in the past 12 months (except for 12 weeks preceding the study)~* Primary hyperparathyroidism, hyperthyroidism or hypothyroidism in last year~* Metabolic bone disease~* Creatinine clearance of \< 50 ml/min~* Documented hypercalcemia or hypercalciuria, nephrolithiasis in the last 5 years~* Pregnancy or lactation~* Treatment in the last 12 months with hormone-replacement therapy~* Anabolic steroids, calcitonin, active vitamin D3 analogues, fluoride or bisphosphonates.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).